FRONT PAGE AMPYRA AUBAGIO AVONEX BETASERON COPAXONE EXTAVIA
Stan's Angels MS News Channel on YouTube GILENYA NOVANTRONE REBIF RITUXAN TECFIDERA TYSABRI
 The Copaxone News Channel
Click Here For My Videos, Advice, Tips, Studies and Trials.
Timothy L. Vollmer, MD
Department of Neurology
University of Colorado Health Sciences Center Professor

Co-Director of the RMMSC at Anschutz Medical Center

Medical Director-Rocky Mountain MS Center
Click here to read my columns
Brian R. Apatoff, MD, PhD
Multiple Sclerosis Institute
Center for Neurological Disorders

Associate Professor Neurology and Neuroscience,

Weill Medical College of Cornell University

Clinical Attending in Neurology,
New York-Presbyterian Hospital
CLICK ON THE RED BUTTON BELOW
You'll get FREE Breaking News Alerts on new MS treatments as they are approved
MS NEWS ARCHIVES: by week
March 2005   
June 2005   
July 2005   
August 2005   
October 2005   
November 2005   
December 2005   
January 2006   
February 2006   
May 2006   
June 2006   
August 2006   
October 2006   
November 2006   
December 2008   
January 2013   
May 2013   
June 2013   
July 2013   
September 2013   
October 2013   
November 2013   
November 2014   
December 2014   
January 2015   
March 2015   
April 2015   
May 2015   
July 2015   
February 2016   

HERE'S A FEW OF OUR 6000+ Facebook & MySpace FRIENDS
Timothy L. Vollmer M.D.
Department of Neurology
University of Colorado Health Sciences Center
Co-Director of the RMMSC at Anschutz Medical Center
and
Medical Director-Rocky Mountain MS Center


Click to view 1280 MS Walk photos!

"MS Can Not
Rob You of Joy"
"I'm an M.D....my Mom has MS and we have a message for everyone."
- Jennifer Hartmark-Hill MD
Beverly Dean

"I've had MS for 2 years...this is the most important advice you'll ever hear."
"This is how I give myself a painless injection."
Heather Johnson

"A helpful tip for newly diagnosed MS patients."
"Important advice on choosing MS medication "
Joyce Moore


This page is powered by Blogger. Isn't yours?

Sunday

 

COPAXONE LEADS IN NEW PRESCRIPTIONS


Teva Pharmaceutical Industries Ltd.  acting CEO Eyal Desheh today said that Copaxone continued to lead in new prescriptions for multiple sclerosis in the third quarter of 2013, despite competition in the market.
In the conference call following the publication of Teva's financial report, Desheh said that Copaxone continued to lead in new prescriptions for multiple sclerosis in the US. "Despite the competition, Copaxone leads in prescriptions and in new prescriptions," he said.

Copaxone sales rose 1% in the third quarter to $1.05 billion.

Copaxone's latest rival is Tecfidera, made by Biogen Idec Inc. (Nasdaq: BIIB), which had $280 million in sales in the third quarter, $50 million more than the analysts' forecasts. Analysts have marked Tecfidera as a blockbuster, which will reach $3 billion in annual sales.

Commenting on Teva's new therapeutic entities (NTE) program, on which the company is pinning its hopes, Desheh predicts that these generic drugs will have billions of dollars in annual sales with higher profit margins than regular generics.

Labels: